v3.26.1
Basis of Presentation (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Product Information [Line Items]      
Research and development expense $ 120,909 $ 124,033  
Conversion of preferred shares 0 0 8,044,884
Operating loss carryforwards $ 4,007,457    
Net operating losses carryforwards, expire date begin to expire in 2027    
Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member] | No Customer [Member]      
Product Information [Line Items]      
Concentration risk percentage 10.00%    
Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member] | One Customer [Member]      
Product Information [Line Items]      
Concentration risk percentage 10.00% 13.80%  
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]      
Product Information [Line Items]      
Concentration risk percentage 16.30%   16.70%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Two [Member]      
Product Information [Line Items]      
Concentration risk percentage     10.20%